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Abstract   
Cancer cells generate protons (H
+
) that are extruded to the extracellular medium 
mainly via the Na
+
/H
+
 exchanger 1 (NHE1), which regulates intracellular pH (pHi) and cell 
proliferation. In primary cultures of human ascites-derived ovarian cancer cells (haOC) we 
assayed whether NHE1 was required for pHi modulation and cell proliferation. Human 
ovary expresses NHE1, which is higher in haOC and A2780 (ovarian cancer cells) 
compared with HOSE cells (normal ovarian cells). Basal pHi and pHi recovery (following a 
NH4Cl pulse) was higher in haOC and A2780, compared with HOSE cells. Zoniporide 
(NHE1 inhibitor) caused intracellular acidification and pHi recovery was independent of 
intracellular buffer capacity, but reduced in NHE1 knockdown A2780 cells. Zoniporide 
reduced the maximal proliferation capacity, cell number, thymidine incorporation, and ki67 
(marker of proliferation) fluorescence in haOC cells. SLC9A1 (for NHE1) amplification 
associated with lower overall patient survival. In conclusion, NHE1 is expressed in human 
ovarian cancer where it has a pro-proliferative role. Increased NHE1 expression and 
activity constitute an unfavourable prognostic factor in these patients. 
 
Keywords: NHE1; pHi; human; ovarian cancer; cell proliferation 
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Abbreviations 
NHEs  Na
+
/H
+
 exchangers 
NHE1  NHE isoform 1 
haOC  human ascites-derived ovarian cancer cells 
K  cell growth rate 
Dt  doubling time 
K/Dt   maximal proliferation capacity 
HMA  5-N,N-hexamethylene amiloride 
V-ATPases V type ATPases 
1/
pHi
E  pHi modulation efficiency 
TCGA  The Cancer Genome Atlas 
CNA  DNA copy-number alterations  
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1. Introduction 
Ovarian cancer is frequently diagnosed at advanced stages [1,2]. Cancer cells 
generate protons (H
+
) [3], which are released by membrane transport systems resulting in 
low extracellular pH (pHo), i.e., acidity, but high intracellular pH (pHi), i.e., alkalization 
[4]. The membrane transport systems involved in pHi control include the sodium (Na
+
)/H
+
 
exchangers (NHEs) [5-8]. NHE isoform 1 (NHE1) predominates and plays critical roles in 
cancer [4,8-10]. NHE1 activity causes intracellular alkalization and extracellular 
acidification [4,11]. Since NHE1 inactivation reduces proliferation of human tumour gastric 
[12] and small lung cancer [13] cells, NHE1 may act as a pro-proliferative factor in human 
tumour cells.  
Mechanisms of pHi control in the human ovary or ascites-cancer cells are unknown 
[8]. Since non-human ovary cells exhibit NHEs activity [14-18], NHE1 may control the 
pHi in the human ovary. However, there are not reports addressing expression or activity of 
NHE1 in human ovarian cancer cells [8]. In this study, we show that functional NHE1 is 
expressed in human ovarian cancer cells playing a critical role in pHi recovery and cell 
proliferation. Thus, NHE1 expression and activity are factors that could result in pHi-
dependent modulation of human ovarian cancer cells proliferation. The latter could be 
relevant to the reduced survival of patients suffering from this disease.  
 
2. Materials and methods 
2.1 Study groups 
 Patients included in this study (3 patients) coursed with ovarian cancer (high degree 
of ovarian serous papillary carcinoma stage IIIC or IV, and endometrioid mix type 
carcinoma with high degree serous differentiation) and were all subjected to primary 
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5 
surgery. Ovarian ascites samples were obtained from the Hospital Clínico UC-CHRISTUS 
in Santiago de Chile (collected by Dr Mauricio Cuello from Division of Obstetrics and 
Gynaecology, School of Medicine, Pontificia Universidad Católica de Chile). Ethnicity of 
patients included in this study was Hispanic. The investigation conforms to the principles 
outlined in the Declaration of Helsinki. Ethics Committee approval from the Faculty of 
Medicine of the Pontificia Universidad Católica de Chile and informed consent of patients 
were obtained. 
 
2.2 Cell culture 
 Primary cultures of human ascites-derived ovarian cancer cells (haOC) were 
established by mixing equal amounts of freshly isolated ascites with MCDB 105 (Sigma-
Aldrich, St Louis, MO, USA)/medium 199 (M199) (Gibco, Grand Island, NY, USA) (1:1 
v/v) culture media containing 10% fetal bovine serum (FBS), 12.5 mmol/L NaHCO3, 4.5 
mmol/L D-glucose, 12.5 mmol/L (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 100 IU/mL penicillin, and 100 µg/mL streptomycin (37ºC, pH 7.4) (MCDB 
105/M199 culture medium). Cells at 70% confluence were harvested with 
trypsin/ethylenediamine tetraacetic acid (EDTA) (0.05/0.2%, 3 minutes, 37°C) and grew up 
to passage 2 [19]. The human ovary cell lines HOSE (normal ovarian surface epithelium) 
and A2780 (ovary cancer cells) (kindly provided by Dr Carmen Romero from the Hospital 
Clínico Universidad de Chile, Santiago, Chile) were maintained in Dulbecco’s modified 
Eagle’s F12 medium (DMEM-F12) (Gibco) containing high (5 mmol/L) D-glucose and 
supplemented with 10% FBS, 16 mmol/L NaHCO3, 15 mmol/L HEPES, 100 IU/mL 
penicillin and 100 µg/mL streptomycin (DMEM-F12 culture medium).   
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2.3 Cell proliferation assay  
 HOSE (6.5 x10
3
 cells/cm
2
), A2780 (2.0 x10
4
 cells/cm
2
), and primary cultures of 
haOC (1.0 x10
4
 cells/cm
2
) were seeded in 24 well plates and cultured for 0-48 hours in 
MCDB 105/M199 for haOC or DMEM-F12 culture media for HOSE and A2780 in the 
absence (Control) or presence of 100 nmol/L zoniporide (NHE1 inhibitor) [20]. Cells were 
resuspended following trypsin/EDTA (0.05/0.2%, 3 minutes, 37°C) digestion and counted 
in a haemocytometer as described [21]. Cell growth rates (K) were derived from the 
exponential growth equation: 
 
K =
ln(Ct )- ln(Ci )
t · ln(e)  
 
where t is time in culture, Ct is number of cells at a given time in culture, Ci is number of 
cells at the beginning of the experiment (i.e., t = 0 hour), and e is 2.7182. The K values 
were expressed as number of cells x10
3
 per cm
2 
of cell culture surface per hour [21]. 
Doubling time (Dt) for cell growth was derived from 0.6932/K and expressed in hours. 
Corrected growth rates by the corresponding doubling times at any given time (i.e., 
maximal proliferation capacity) in culture was estimated from K/Dt.  
 
2.4  Thymidine incorporation 
 Cells in the logarithmic phase of cell growth (i.e., 40-45% confluence) were 
incubated with [
3
H]thymidine (2 µCi/mL, 6-[
3
H]thymidine, 6.7 Ci/mmol (NEN, Dreieich, 
Germany), 48 hours, 37ºC) in MCDB105/M199 for haOC or DMEM-F12 culture media for 
HOSE and A2780 cells in the absence or presence of zoniporide. After this incubation 
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period the cells were rinsed with phosphate-buffered salt (PBS) solution ((mmol/L) NaCl 
130, KCl 2.7, Na2HPO4 0.8, KH2PO4 1.4 (pH 7.4, 4ºC)) and exposed to 5% trichloroacetic 
acid (TCA, 200 mL, 10 minutes). TCA was removed and cells rinsed with 99% methanol 
(200 mL) and digested with 25 mmol/L formic acid for radioactivity determination as 
described [21].  
 
2.5 Measurement of pHi  
 Cell monolayers in 96 well plates (70% confluence) were incubated for 10 minutes 
at 37°C with the fluorescent pH sensitive probe 2,7-bicarboxyethyl-5,6-carboxyfluorescein 
acetoxymethyl ester (BCECF-AM, 12 mol/L) (Sigma-Aldrich), as described [22]. Some 
experiments were also performed in cells incubated for 1 minute with BCECF-AM, and the 
results for pHi were not significantly different from 10 minutes incubation (not shown). 
The excess of probe was removed by rinse three times with control solution (CS) 
((mmol/L) NaCl 145, KCl 5, NaH2PO4 1 Na2SO4 1, CaCl2 1.8, MgCl2 1, HEPES 30, D-
glucose 5 (pH 7.4, 37ºC). The fluorescence ratios was registered in a fluorimeter Tecan 
M200Pro (Untersbergstr, Austria) after alternate cell excitation at 440 and 490 nm, and 
emission at 530 nm registered every 2 seconds interval for a period of 150 seconds. pHi 
was estimated by interpolation of emission ratios using standard calibration curves in cells 
incubated with 10 µmol/L nigericin in a calibrating solution ((mmol/L) KCl 130, NaCl 20, 
CaCl2 1, MgCl2 1, HEPES 5 (pH 6.2, 7.2, or 8.2)) as described [21,22]. Cells were 
incubated without or with 5 μmol/L 5-N,N-hexamethylene amiloride (HMA, NHEs general 
inhibitor) [23], 100 nmol/L zoniporide [20], 0.1 µmol/L concanamycin A (V type ATPases 
(V-ATPases) inhibitor) [24], and 10 µmol/L Schering 28080 (H
+
/K
+ 
ATPase inhibitor) [25]. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
8 
2.6 Recovery of pHi  
 The pHi recovery was examined by applying the NH4Cl pulse technique [21,22]. In 
brief, BCECF-AM loaded cells were incubated in CS until the basal pHi was stabilized (3 
minutes). Cells were exposed (2 minutes) to CS supplemented with NH4Cl (NH4Cl/CS 
solution) ((mmol/L) NaCl 121, KCl 5.4, CaCl2 1, KH2PO4 0.4, MgCl2 0.5, MgSO4 0.4, 
Na2HPO4 0.3, HEPES 10, D-glucose 0.6, NH4Cl 20 (pH 7.4, 37°C)). After this incubation 
period the NH4Cl/CS solution was replaced by rinsing the cells with CS free of NH4Cl 
(0Na
+
/CS) ((mmol/L) N-methyl-D-glucamine (NMDG) 120, KCl 5, CaCl2 1.8, MgCl2 1, 
HEPES 30, D-glucose 5 (pH 7.4, 37°C)), without or with HMA, zoniporide, concanamycin 
A and/or Schering 28080 as above.  
 Recovery rates of pHi (dpHi/dt) were calculated from data collected for the first 60 
seconds of the recovery (i.e., after removing the NH4Cl load) and fitted by a first order 
lineal regression as described [21,22]. The results were expressed in pHi units/minute. The 
NHEs-mediated component of dpHi/dt (
NHEs
f) was estimated from: 
 
 NHEs f =
HMAa -d
HMA+CA+Scha -d
·100 
 
where 
HMA is dpHi/dt inhibited by HMA, HMA+CA+Sch is dpHi/dt inhibited by HMA + 
concanamycin A + Schering, and  represents the corresponding remaining dpHi/dt 
(background) on each condition. The involvement of NHE1 (
NHE1
f) in the 
NHEs
f component 
was estimated by 
NHE1
f = 
NHEs
f – Z, where Z is dpHi/dt inhibited by zoniporide. The 
involvement of V-ATPase (
V
f) and H
+
/K
+ 
ATPase (
H/K
f) components were estimated as for 
NHEs
f considering 
CA (dpHi/dt inhibited by concanamycin A) or Sch (dpHi/dt inhibited by 
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9 
Schering) and 
HMA+Z+Sch (dpHi/dt inhibited by HMA + zoniporide + Schering) or 
HMA+Z+CA (dpHi/dt inhibited by HMA + zoniporide + concanamycin A), respectively. 
 Initial velocity for pHi recovery was derived from slope of linear phase of dpHi/dt 
adjusted to the one phase exponential association equation considering the least squares fit 
[26]: 
 
vi =
dpHi
dt
× (1- e-(k×t ))  
 
where vi is initial velocity, dpHi/dt is mayor recovery rate at a given time (t) (in this study t 
= 0.03 seconds) and e and k are constants. The capacity of cells to change the pHi value in 
certain units of pHi as a result in the dpHi/dt modifications (i.e., efficiency of pHi 
modulation (1/
pHi
E)) was estimated from:  
 
1/ pHiE =
(DdpHi / dt)
DpHi
·a  
 
where dpHi/dt is the change in dpHi/dt from control, pHi is the change in pHi from 
control, and  is a given pHi unit.  
 
2.7 Intrinsic buffering capacity 
 The ability of intrinsic cellular components to buffer changes in pHi, i.e., 
intracellular buffer capacity (i), was measured as described [21]. After determining the 
basal pHi the cells were incubated in a 0.5 mmol/L KCl-containing 0Na
+
/CS plus Schering 
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28080 + concanamycin A (pH 7.4, 37ºC) until the pHi was stabilized under this 
experimental condition (~3 minutes). Cells were then incubated in the latter solution 
containing decreasing concentrations of NH4Cl (50, 20, 10, 5, 2.5 or 1 mmol/L). To assay 
the effect of each of the concentrations of NH4Cl the cells were rinsed three times with the 
corresponding lower NH4Cl concentration used in this study. The i was calculated from 
the expression: 
 
bi =
D[NH4
+]i
DpHi  
 
where the intracellular NH4
+
 concentration ([NH4
+
]i) was obtained from the Henderson-
Hasselbalch equation on the assumption that [NH3]i (intracellular NH3) was equivalent to 
[NH3]o (extracellular NH3), and  pHi is the fraction of change in units of pHi value.  
 Knowing the dpHi/dt and the i values (at similar pHi values in each cell type), the 
rate of overall transmembrane H
+
 flux (JH+) was calculated from the following expression: 
 
J
H+
=
dpHi
dt
·bi
 
 
2.8 Western blotting  
 Total protein was obtained from conﬂuent cells rinsed (x2) with ice-cold PBS and 
harvested in 100 µL of lysis buffer (100 mmol/L NaCl, 10 mmol/L Na4P2O7 x10-H2O, 10 
mmol/L NaF, 1% Triton X100, 1 mmol/L sodium orthovanadate, 50 mg/mL leupeptin, 20 
mmol/L HEPES (pH 7.4, 4ºC) as described [22]. Cells were sonicated (6 cycles, 5 seconds, 
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100 W, 4ºC) and total protein was separated by centrifugation (13500 g, 15 minutes, 4°C). 
Proteins (70 g) were separated by polyacrylamide gel (8%) electrophoresis, transferred to 
Immobilon-P polyvinylidene difluoride membranes (BioRad Laboratories, Hertfordshire, 
UK) and probed with primary monoclonal rabbit anti-NHE1 (1:500 dilution, 12 hours, 4ºC) 
or monoclonal mouse anti-β-actin (1:2500 dilution, internal reference) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) antibodies. The membranes were rinsed in 
PBS/0.1% Tween 20 (PBS-T) and further incubated (1 hour) in PBS-T/0.2% bovine serum 
albumin (BSA) containing secondary horseradish peroxidase-conjugated goat anti-rabbit or 
anti-mouse antibodies (Thermo Scientific, Rockford, IL, USA). Proteins were detected by 
enhanced chemiluminescence in a ChemiDoc-It 510 Imagen System (UVP, LCC Upland, 
CA, USA) and quantified by densitometry [22]. 
 
2.9 Immunofluorescence microscopy 
 Paraformaldehyde-fixed, paraffin-embedded ovarian cancer serial sections (4 µm) 
were dewaxed and subsequently rehydrated with serial incubations using 100, 95, or 70% 
ethanol solutions. Histological slices were permeabilized (3% Tween 20, 10 minutes) and 
blocked with defatted-cow milk (5% in PBS, 1 hour, 22ºC). NHE1, cytokeratin-7 (CK-7) 
(marker for epithelial cells) and (marker for proliferation) were immunolocalized following 
incubation (overnight at 4°C) with primary policlonal rabbit anti-NHE1 (1:200 dilution) 
(Santa Cruz Biotechnology), monoclonal mouse anti-CK-7 (1:200 dilution) (Dako, 
Glostrup, Denmark) or anti-ki67 (1:50 dilution) (Thermo Scientific, Rockford, IL, USA) in 
PBS containing 2% BSA (PBS/2% BSA) and followed by incubation (1 hour, 22°C) with 
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the secondary antibody Alexa Fluor 568 goat anti-rabbit or anti-mouse IgG (H+L, 
λexc/λem: 578/603 nm, 1:750) (Life Technologies).  
 Cells were grown on microscope cover glasses (6 x10
4
 cells per slide) (Sail Brand, 
Shangai, China) in corresponding culture media to 70% confluence as described [27]. In 
brief, cells were fixed (4% paraformaldehyde, 15 minutes), permeabilized (0.1% Triton X-
100, 10 minutes) and blocked (PBS/2% BSA, 1 hour, 22ºC). NHE1 and ki67 were 
immunolocalized following incubation (overnight at 4°C) with primary policlonal rabbit 
anti-NHE1 (1:200 dilution) or monoclonal mouse anti-ki67 (1:50 dilution) in PBS/2% BSA 
and followed by incubation (1 hour, 22°C) with the secondary antibody Alexa Fluor 488 
goat anti-mouse IgG (H+L, λexc/λem: 488/519 nm, 1:750 dilution) or Alexa Fluor 568 goat 
anti-rabbit IgG (H+L, λexc/λem: 578/603 nm, 1:750 dilution) (Life Technologies). Cell 
nuclei were stained with Hoescht 33342 (4 µmol/L, 10 minutes, 22ºC) (Thermo Scientific). 
Images were obtained under an EVOS FL Imaging System (AMF 4300) (Life 
Technologies). Fluorescence quantification was performed by the method of Corrected 
Total Fluorescence Intensity (CTCF) as described [28] in regions of optical interest (ROI) 
in serial slices. ROI was defined as a section of the tissue that was positive (epithelial) or 
negative (stroma) for the epithelial marker CK-7 where NHE1 and ki67 staining was 
determined. Images were processed with Image J version 1.48v (Wayne Rusband NIH, 
USA).  
 
2.10 NHE1 suppression 
 Suppression of NHE1 expression was done using the commercially available short 
interference RNAs (siRNA) NHE-1 siRNA (h) or control sequence (siC) (Santa Cruz 
Biotechnology) following manufacturer’s instructions 
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(http://datasheets.scbt.com/siRNA_protocol.pdf). HOSE and A2780 cells knockdown for 
NHE1 (
KD-NHE1
HOSE and 
KD-NHE1
A2780, respectively) were generated. haOC cells were not 
viable in vitro under this approach, thus 
KD-NHE1
haOC cells was not possible.  
 
2.11 TCGA data analysis 
 Genomic, mRNA expression and clinical information of high-grade serous cancer 
were obtained in silico from The Cancer Genome Atlas Ovarian Cancer 
(https://confluence.broadinstitute.org/display/GDAC/Home). Analyses of patient’s survival 
and NHE1 signalling pathway were performed in cBioPortal platform for Cancer Genomics 
(http://www.cbioportal.org/study.do?cancer_study_id=ov_tcga) according to previously 
published protocols [29,30]. 
 
2.12 Statistical analysis  
 The values are mean ± S.E.M., where n indicates the number of different biological 
samples (3 ascites from patients with ovarian cancer) and corresponding cell cultures with 
3-4 replicates per experiment. Comparisons between two groups were performed by means 
of Student’s unpaired t-test. The difference between more than two groups was performed 
by ANOVA (one or two ways). If the ANOVA demonstrated a significant interaction 
between variables, post hoc analyses were performed by the multiple-comparison 
Bonferroni test. To estimate the correlation between NHE1 and ki67 expression in tissue 
samples, the correlation analysis was performed using Pearson’s correlation coefficient (r). 
Patient survival analyses were addressed by Kaplan Meier methodology using log-rank, 
Wilcoxon parameters. P<0.05 value was considered statistically different. The statistical 
software GraphPad InStat 3.0b and GraphPad Prism 7.0b (GraphPad Software Inc., San 
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Diego, CA, USA) were used for data analysis. P<0.05 was considered statistically 
significant.  
 
3. Results 
3.1 NHE1 expression in human ovary  
The first goal of this study was to determine whether NHE1 was expressed in 
human ovarian cancer tissue. Ovarian cancer tissue was positive for NHE1 and CK7 
(Figure 1A). NHE1 was detected in tumour epithelium and stroma (Figure 1B), with higher 
fluorescence at the epithelium, compared with stroma (Figure 1C). We then assayed 
whether NHE1 was expressed in cultured human ovarian cancer cells. NHE1 protein was 
detected in all cell types (Figure 2A) and was higher in haOC and A2780 compared with 
HOSE cells. NHE1 protein was detected in the cells and in the cell periphery (Figure 2B). 
 
3.2 Basal pHi and dpHi/dt  
Since NHE1 expression associates with pHi modulation in several tumour cells [4-
10], we determined basal pHi and the potential functional involvement of this and other 
membrane transport mechanisms to regulate intracellular H
+
 content. Basal pHi in haOC 
and A2780 was higher than in HOSE cells (Table 1). Zoniporide and HMA, but not 
concanamycin A or Schering 28080 caused intracellular acidification in all cell types. To 
estimate the capacity of cells to recover from an acidic pHi cells were subjected to the 
NH4Cl pulse assay [21-23]. The acidic pHi caused by the NH4Cl pulse was fully restored 
after ~3 minutes (Figure 3A). Basal dpHi/dt (Table 1) and vi for dpHi/dt (Figure 3B) in 
haOC (vi = 10.2 ± 0.001 pHi units/minute) and A2780 cells (vi = 9.8 ± 0.002 pHi 
units/minute) were higher compared with HOSE cells (vi = 7.8 ± 0.001 pHi units/minute).  
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3.3 ßi and JH+ 
Since a change in basal pHi and dpHi/dt depends on the ßi capacity of cells [21], 
this parameter was estimated and used to determine JH+. The results show that ßi increased 
as pHi value decreased (Figure 3C) and ßi at equal pHi after a 20 mmol/L NH4Cl pulse 
(pHi HOSE = 6.95, pHi haOC = 6.93, pHi A2780 = 6.95) were similar in all cell types 
(Figure 3D). In addition, JH
+
 was higher in haOC and A2780 compared with HOSE cells 
(Figure 3E). 
 
3.4 NHE1, V-ATPase, and H
+
/K
+ 
ATPase involvement on dpHi/dt 
To know the relative contribution of the membrane transport mechanisms involved 
in the regulation of pHi, the dpH/dt was measured in the absence or presence of specific 
inhibitors for NHE1, V-ATPase, and H
+
/K
+ 
ATPase. The results show that HMA reduced 
dpHi/dt in all cell types (Table 1). Partial inhibition was detected in HOSE and A2780 
cells; however, HMA abolished dpHi/dt in haOC cells (Figure 4A). Zoniporide caused a 
partial reduction of dpHi/dt in HOSE and haOC cells, which was similar to HMA effect in 
A2780 cells. Concanamycin A and Schering 28080 caused partial reduction (47-59%) of 
dpHi/dt only in 2780 cells. The 
NHEs
f component accounted for a fraction of dpHi/dt 
similar in HOSE and haOC cells (Figure 4B). However, 
NHEs
f accounted for almost all 
dpHi/dt in A2780 cells. Involvement of 
NHE1
f component in 
NHEs
f resulted in a fraction of 
dpHi/dt that was similar in HOSE and haOC cells; however, in A2780 cells accounted for 
all the 
NHEs
f component. The 
V
f and 
H/K
f components were detected only in A2780 cells. 
With the aim to corroborate that NHE1 expression is required for a pHi recovery, 
cells knockdown for this protein were used to estimate dpHi/dt. The NHE1 protein 
abundance was lower in 
KD-NHE1
HOSE and 
KD-NHE1
A2780 cells compared with cells 
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expressing NHE1 (Figure 4C). The 
KD-NHE1
HOSE and 
KD-NHE1
A2780 cells also show lower 
dpHi/dt compared with cells expressing NHE1 (Figure 4D).  
 
3.5 Cell proliferation and NHE1 and ki67 correlation 
Since an acidic pHo due to increased activity of NHE1 is associated with increased 
tumour cells proliferation [12,13], cell proliferation was assayed in the presence of a NHE1 
inhibitor. The results show that zoniporide reduced proliferation (Figure 5A) and the K/Dt 
in all cell types (Table 2). The reduction in the K/Dt was less pronounced in A2780 
compared with HOSE or haOC cells. Cell growth rate was higher, but doubling times were 
lower in A2780 cells compared with HOSE or haOC cells. Zoniporide decreased growth 
rate and increased the doubling time only in haOC cells. Results in the kinetics of cell 
growth were complemented with an estimation of the changes in the actual cell number 
changes and nucleic acid turnover. The cell number and [
3
H]thymidine incorporation were 
reduced by zoniporide (Figure 5B). Additionally, the number of ki67 positive cells (marker 
for cell proliferation) in the presence of zoniporide was lower in A2780 and haOC, but 
unaltered in HOSE cells.  
To confirm a parallel increase in NHE1 and ki67 protein expression in human 
ovarian tissue, a potential correlation between these proteins expression was analysed. The 
results show that NHE1 and ki67 proteins were detected in the same regions in ovarian 
cancer tissues, with a positive correlation for NHE1 and ki67 protein abundances (Figure 
5C). Additionally, the cell number counted in 
KD-NHE1
HOSE and 
KD-NHE1
A2780 cells was 
lower compared with these cells expressing NHE1 (Figure 5D).  
 
3.6 SLC9A1 and overall survival  
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In the aim of knowing whether NHE1 overexpression associates with adverse 
prognostic in patients with high-grade serous ovarian cancer, we analysed in silico the 
DNA copy-number alterations (CAN) for SLC9A1. Analysis of the CNA for this gene in 
human ovarian cancer reveals that 4% of cases will present with genetic changes including 
amplification (nine patients), deep deletions (one patients), and upregulation (six patients) 
or downregulation (two patients) of mRNA expression (Figure 6A). SLC9A1 mRNA 
expression increases according to the type of CNA alteration in patients with high-serous 
ovarian cancer (Figure 6B). The analysis in silico reveals that SLC9A1 is in direct-pathway 
with endothelin-1 (END1)/endothelin receptor A (ENDRA) and with epidermal growth 
factor (EGF)/EGF receptor (EGFR) in patients with ovarian cancer (Figure 6C). SLC9A1 
amplification associated with reduced overall survival (50%) compared with patients 
without changes in SLC9A1 (diploid (98 patients) (41.4 versus 20.5 months in nine patients 
with SLC9A1 amplification, respectively) (Log-rank = 0.0005, Wilcoxon = 0.0013) or with 
mild CNA alteration (shallow deletion (108 patients) or gain (63 patients)) (Figure 6D). 
There was not a difference between amplification and homologous deletions (5 patients, 
Log-rank = 0.36, Wilcoxon = 0.68), or homologous deletion and overall survival when 
compared with unaltered or mild CNA alteration. 
 
4. Discussion 
This study shows that NHE1 is expressed in the human ovarian cancer and primary 
cultures of human ascites ovarian cancer cells (haOC). Tumour cells show intracellular 
alkalization compared with normal tissues [4,31,32]. This phenomenon depends on the 
expression of membrane transport systems for H
+
 removal [8,33]. haOC cells show pHi 
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values higher (~0.35 pHi units) than in non-tumour cells, suggesting that pHi regulation is 
altered by this pathology. This condition may be responsible for cell malignancy since an 
increase in 0.2-0.4 pHi units associates with higher cancer cell proliferation [4,21,33]. 
NHE1, 2, 3, and 4 are critical regulators of pHi in tumour tissues [8,34]. Our results show 
that NHE1 protein is expressed in CK7 positive tumour epithelium in the human ovary. 
Additionally, haOC cells show increased NHE1 expression (~12 fold) compared with non-
tumour cells, suggesting its potential role in this type of cancer. haOC cells also show 
increased dpHi/dt and pHi that was comparable to that in non-tumour cells, suggesting that 
intracellular alkalization may result from a higher dpHi/dt. Indeed, increased vi of dpHi/dt 
in haOC agrees with other cancer cells [4,8,31,32]. Since haOC and non-tumour cells 
intrinsic buffer capacity (ßi) were similar, increased dpHi/dt and JH
+
 are not due to 
abnormal cell capacity to buffer a change in pHi. Interestingly, the ßi values determined in 
HOSE, haOC, and A2780 cells are in the same range as for other tumour cells such as T84 
cells (~31 (mmol/L)/pHi units) [22,35], and lower than in non-tumour MDCK cells (~110 
(mmol/L)/pHi units) [21]. The differences in the βi values could be due to specie 
differences (human versus dog) since the experimental conditions to determine this 
parameter were similar in these studies.  
HMA reduced the dpHi/dt and pHi, suggesting a role for NHEs in these phenomena. 
Since HMA-reduced pHi was higher (~1.5 fold) in haOC than non-tumour cells, haOC cells 
are more sensitive to NHEs activity-dependent pHi regulation. Same results were found in 
cells treated with zoniporide. Thus, haOC cells require NHE1 activity by a larger fraction 
(
NHE1
f / 
NHEs
f ~0.8), in this phenomenon. 
NHE1
f involvement to increase pHi is supported by 
the lower dpHi/dt detected in NHE1-knockdown ovarian tumour cells. 
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The maximal proliferative capacity (K/Dt) of haOC was similar to non-tumour cells, 
suggesting that ovarian cancer does not alter ovarian cells proliferation. NHE1’s activity 
plays a preferential role in haOC cells proliferation since zoniporide-reduced K/Dt was ~1.3 
fold higher than non-tumour cells. Since a positive correlation between NHE1 and ki67 
protein abundance was found (i.e., NHE1-expression dependent proliferation), and 
zoniporide reduces K/Dt (i.e., NHE1-activity dependent proliferation), NHE1 expression 
and activity are required for haOC cells proliferation. The latter is supported by results 
showing zoniporide-reduced haOC cell number and DNA turnover. 
haOC cells show pHi modulation efficiency (1/
pHi
E ~4.74 pHi units/minute) lower 
than in non-tumour cells. Thus, haOC cells may count with a less efficient mechanism 
protecting for intracellular acidification than in non-tumour cells. Zoniporide-reduced K/Dt 
in haOC cells may depend on a lower 1/
pHi
E in haOC (1/
pHi
E ~0.17 pHi units/minute in the 
presence of zoniporide) compared with non-tumour cells (1/
pHi
E ~0.11 pHi units/minute in 
the presence of zoniporide) [(K/Dt)/1/
pHi
E 0.31 in haOC and 0.11 in HOSE cells]. This 
mechanism will favour tumour cells survival since intracellular acidification causes cell 
death [36-38]. Interestingly, a high pHi favours the transition from phase S to G2/M in the 
cell cycle and DNA/RNA synthesis [6,39]. Our results show that zoniporide reduced 
[
3
H]thymidine incorporation. Thus, blocking NHE1 activity leads to acidic pHi-dependent 
reduced proliferation likely due to reduced cell cycle progression of haOC cells. These 
findings are supported by the reduced dpHi/dt detected in A2780 and non-tumour NHE 
knockdown cells. Thus, NHE1 expression and activity are pro-proliferative factors in 
human ovarian cells. 
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Parallel analysis of CNA in SLC9A1 (for NHE1) revealed that a fraction of patients 
showed with CNA including higher amplification. Since SLC9A1 mRNA expression is 
increased depending on CNA alterations, this change in SLC9A1 could determine human 
ovarian cancer stage. CNA alterations may modulate the SLC9A1 expression by endothelin-
1 and epidermal growth factor, complementing reports involving endothelin-1 and 
endothelin receptor A in this type of cancer [40] and endothelin-1 in combination with -
arrestin-1 activation increasing chemoresistance [41]. Equally, activation of epidermal 
growth factor/epidermal growth factor receptor signalling is involved in higher 
angiogenesis [42] and resistance to paclitaxel [43] in human ovarian cancer. Higher serum 
epidermal growth factor [44] and endothelin-1 in the peritoneal fluid in patients with 
malignant ascites [45,46] are reported in human ovarian cancer. Thus, epidermal growth 
factor and endothelin-1 modulation of SLC9A1 expression and their involvement in ovarian 
cancer are suggested. Certainly future experiments should be considered to confirm the 
potential role of endothelin-1 and epidermal growth factor in the alterations in pHi 
modulation and cell proliferation in haOC and other ovarian cancer cells. SLC9A1 
amplification results in lower patients overall survival. Thus, NHE1 overexpression is an 
adverse prognostic factor in patients with high-grade serous ovarian cancer presenting 
alterations in these signalling pathways.   
 In summary, human ovary expresses NHE1 membrane transporters whose 
expression and activity are increased in human ascites cells from ovary cancer, suggesting a 
role for this protein in this disease. NHE1 contributes to pHi recovery by a higher 
expression in tumour cells acting as a pro-proliferative factor in human ovary tumour cells. 
Additionally, higher SLC9A1 expression may constitute worse survival prognostic factor in 
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patients with ovarian cancer. Since antineoplastic drugs treatment of patients with ovary 
cancer has various and serious adverse effect sounds reasonable to propose the use of a 
lower concentration of these drugs together with NHE1 inhibitors to obtain a similar 
inhibition of cancer growth in future therapy. Supporting this possibility are the findings 
showing that inhibition of NHE1 activity results in a higher sensitivity to paclitaxel in 
breath cancer [47]. Thus, strategies to control NHE1 expression and activity in patients 
with ovary cancer could be of benefit reducing the adverse patient’s outcome of this 
disease.  
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Figure 1. NHE1 expression in human ovary. A. NHE1 and cytokeratin-7 (CK7) proteins 
(arrows) detected by immunofluorescence in human ovarian cancer tissue sections. B. 
NHE1 protein at the epithelial origin (Te) and stroma non-epithelial (S) regions 
(dotted line limits Te and S). C. NHE1 immunosignal in Te and S from B. Bars: 50 
µm in A and 200 µm in B. *P<0.05. Mean ± S.E.M. (n = 3).  
 
Figure 2. NHE1 protein abundance in human ovarian tumour cells. A. Western blot for 
NHE1 and -actin (internal reference) protein abundance in HOSE, A2780, and 
haOC cells. Lower panel: NHE1/-actin ratio densitometries normalized to 1 in 
HOSE. B. Immunofluorescence for NHE1 (arrows show NHE1). Bars: 10 µm. 
*P<0.01. Mean ± S.E.M. (n = 3-7). 
 
Figure 3. pHi recovery. A. HOSE, A2780, and haOC cells were exposed to 20 mmol/L 
NH4Cl (+NH4Cl). NH4Cl was removed (–NH4Cl) and initial rates of pHi recovery 
were calculated (see Methods). B. Initial velocity for pHi recovery as in A. C. 
Intracellular buffering capacity (i) determined as described in Methods. D. i for 
corresponding pHi from data in C. E. H
+
 flux rates (JH+) (see Methods). *P<0.05 
versus all other values. Values are mean ± S.E.M. (n = 3-10).  
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Figure 4. NHE1 involvement in pHi recovery. A. pHi recovery rates (dpHi/dt) in HOSE, 
A2780, and haOC cells without (Control, 100%) or with 5 μmol/L 5-N,N-
hexamethylene amiloride (HMA), 100 nmol/L zoniporide (Z), 0.1 µmol/L 
concanamycin A (CA), and/or 10 µmol/L Schering 28080 (Sch). B. dpHi/dt fraction 
mediated by NHEs (
NHEs
f), V type ATPases (
V
f), or H
+
/K
+ 
ATPase (
H/K
f) components. 
Arrows indicate the dpHi/dt fraction mediated by NHE1 (
NHE1
f) of 
NHEs
f component 
(see Methods). ‘All’ is all components of dpH/dt. C. Western blot for NHE1 and -
actin (internal reference) protein abundance in HOSE and A2780 expressing NHE1 
(
NHE1
HOSE, 
NHE1
A2780) or NHE1 knockdown (
KD-NHE1
HOSE,
 KD-NHE1
A2780) cells. 
Lower panel: NHE1/-actin ratio densitometries normalized to 1 in NHE1HOSE cells. 
D. dpH/dt in cells as in C. In A: *P<0.04 versus Control, †P<0.05 versus all other 
corresponding values, ‡P<0.05 versus all other values except for Z in HOSE cells. In 
B: *P<0.05 versus all other values, †P<0.04 and ‡P<0.05 versus corresponding 
values in HOSE and haOC cells. In C and D: *P<0.05 versus corresponding values in 
NHE1
HOSE or 
NHE1
A2780. In D: †P<0.05 versus all other values. Values are mean ± 
S.E.M. (n = 3-10).  
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Figure 5. NHE1 involvement in cell proliferation. A. HOSE, A2780, and haOC cells 
cultured in the absence (Control) or presence of 100 nmol/L zoniporide. Cell number 
was determined in a haemocytometer (see Methods). B. Cell number, thymidine 
incorporation, and ki67 positive cells in the absence (Control) or presence of 
zoniporide (+Zoniporide) as in A. C. Immunofluorescence for NHE1 and ki67 
protein in human ovarian cancer tissue sections (bars: 50 µm). The graph represents 
NHE1 versus ki67 immunosignal adjusted to a first-order equation (Pearson’s 
correlation coefficient (r) = 0.83, goodness-of-fit R
2
 = 0.672, P<0.0001, n = 32 ROIs 
in 3 patients). (D) Cell number in HOSE and A2780 expressing NHE1 (
NHE1
HOSE, 
NHE1
A2780) or NHE1 knockdown cells (
KD-NHE1
HOSE,
 KD-NHE1
A2780). Values are 
normalized to 1 in 
NHE1
HOSE or 
NHE1
A2780 cells. In B: *P<0.05 versus Control. In 
D, *P<0.04 versus corresponding 
NHE1
HOSE or 
NHE1
A2780. Values are mean ± 
S.E.M. (n = 3-10). 
 
Figure 6. NHE1 expression and survival in patients with ovarian cancer. A. Analysis 
of the DNA copy-number alterations (CNA) for SLC9A1 in human ovarian cancer 
(The Cancer Genome Atlas Ovarian Cancer (TCGA) database) (the number of cases 
with the indicated genetic alterations (Genetic Alteration) is given). B. Relation 
between mRNA number of copies and alterations in CNA of SLC9A1 in patients with 
high-grade serous ovarian cancer. C. Representation of NHE1 pathway as in C. Green 
arrows depicts direct-modulatory pathway of SLC9A1 by endothelin-1 
(END1)/endothelin receptor A (ENDRA) and epidermal growth factor (EGF)/EGF 
receptor (EGFR). D. Overall survival of patients with ovarian cancer according to the 
indicated CNA alterations (by cBioPortal platform for Cancer Genomics). 
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Table 1. pHi and pHi recovery rates in human ovary cells  
  HOSE  A2780  haOC  
pHi 
       
       
 Control  7.391  0.034  7.621  0.044 *  7.840  0.053 *  
HMA  7.262  0.112 †  7.574  0.145 *†  7.648  0.095 *†  
Zoniporide (Z)  7.270  0.079 †  7.383  0.161 †  7.656  0.069 *†  
Concanamycin A (CA)  7.601  0.183  7.546  0.031  7.858  0.196  
Schering 28080 (Sch)  7.692  0.132  7.607  0.043  7.782  0.163  
dpHi/dt (pHi units/minute) 
     
     
Control  0.114  0.081  0.152  0.025 *  0.194  0.050 *  
HMA  0.018  0.007 *  0.026  0.017 *  0.004  0.001 *  
Z  0.051  0.006 *†  0.026  0.008 *  0.049  0.006 *†  
CA  0.110  0.010 ‡  0.062  0.018 *‡  0.196  0.086 ‡  
Sch  0.106  0.013 ‡  0.080  0.011 *‡  0.157  0.082 ‡  
HMA + Z  0.025  0.002 *§  0.025  0.017 *§  0.001  0.001 *§  
HMA + CA  0.012  0.015 *§  0.034  0.008 *§  0.001  0.005 *§  
HMA + Sch  0.014  0.009 *§  0.037  0.011 *§  0.001  0.030 *§  
HMA + Z + CA  0.012  0.029 *§  0.039  0.016 *§  0.009  0.001 *§  
HMA + Z + Sch  0.025  0.004 *§  0.033  0.018 *§  0.005  0.014 *§  
HMA + CA + Sch  0.011  0.002 *§  0.012  0.007 *§  0.011  0.002 *§  
HMA + Z + CA + Sch  0.026  0.016 *§  0.006  0.011 *§  0.001  0.023 *§  
Z + CA  0.053  0.032 *¶  0.031  0.010 *#  0.047  0.011 *¶  
Z + Sch  0.061  0.057 *¶  0.022  0.015 *#  0.037  0.009 *¶  
Z + CA + Sch  0.051  0.055 *¶  0.011  0.015 *#  0.037  0.009 *¶  
CA + Sch  0.112  0.013 $  0.033  0.025 *£  0.120  0.051 $  
Legend for Table 1 in the next page 
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Legend for Table 1. 
The intracellular pH (pHi) was measured in BCECF-AM–preloaded HOSE, A2780 and 
human ascites ovarian cancer cells (haOC) in the absence (Control) or presence of 5 
μmol/L 5-N,N-hexamethylene amiloride (HMA) (NHEs general inhibitor), 100 nmol/L 
zoniporide (Z) (NHE1 inhibitor), 0.1 µmol/L concanamycin A (CA) (V type ATPases 
inhibitor), or 10 µmol/L Schering 28080 (Sch) (H
+
/K
+ 
ATPase inhibitor) as described in 
Materials and Methods. Initial rates of pHi recovery (dpHi/dt) were determined in cells 
subjected to an acid pulse (NH4Cl assay) as above. In pHi section: *P<0.05 versus Control 
in HOSE. †P<0.05 versus corresponding Control values. In dpHi/dt section: *P<0.05 
versus Control in HOSE or in the corresponding cell type. †P<0.05 versus all other 
corresponding values except Z + CA, Z + Sch, and Z + Ca + Sch. ‡P<0.05 versus 
corresponding HMA and Z. §P<0.05 versus corresponding values in Z, CA, or Sch. 
¶P<0.05 versus corresponding values in HMA (alone or in mix with other inhibitors), CA, 
and Sch. #P<0.05 versus corresponding values in CA or Sch. $P<0.05 versus 
corresponding values in HMA and Z (alone or in mix with other inhibitors), CA or Sch. 
£P<0.05 versus all other corresponding values except CA and Sch. Values are mean  
S.E.M. (n = 3-22). 
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Table 2. Effect of zoniporide on the parameters for human ovary cells proliferation. 
  K 
(1/hour) 
 
Dt 
(hour) 
 
K/Dt 
(1/(hour)
2
) 
 
        
HOSE        
 Control  0.01702  0.00477  41  11  0.00042  0.00011  
 Zoniporide  0.01131  0.00402  61  22  0.00019  0.00007 *  
        
A2780        
 Control  0.03949  0.00304 †  17  1 †  0.00232  0.00016 †  
 Zoniporide  0.03328  0.00401 †  21  3 †  0.00158  0.00023 *†  
        
haOC        
 Control  0.01357  0.00131  51  1  0.00027  0.00003  
 Zoniporide  0.00791  0.00074 *  88  1 *  0.00009  0.00001 *  
 
HOSE, A2780, and human ascites ovarian cancer cells (haOC) cells were seeded in 24-well 
plates (2.05 cm
2
 surface) and cultured for 48 hours in primary culture medium without 
(Control) or with 100 nmol/L zoniporide. Cell number was estimated by counting at 
different periods of time and cell growth rates (K) and doubling time (Dt) for cell growth 
was defined as described in Materials and Methods. K/Dt represents corrected cell growth 
rate by doubling times (maximal proliferation capacity) of cells in culture. *P<0.05 versus 
corresponding Control values. †P<0.05 versus corresponding values in HOSE and haOC 
cells. Values are mean  S.E.M. (n = 3-22). 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
41 
 
Fig. 6 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
42 
Highlights 
 
 Human ovary tissue expresses functional Na+/H+ exchanger 1 (NHE1) isoform. 
 Expression of NHE1 is increased in human ovarian tumour epithelial cells.  
 NHE1 regulates intracellular pH in human ovarian tumour cells. 
 NHE1 activity is a pro-proliferative factor in human ovarian tumour cells. 
 High NHE1 expression and activity associate with lower overall patients' survival 
